and the glucose rate of appearance (R a) of ingested glucose in the presence of physiological changes of insulin and glucose concentrations. However, S I of OMM measures the overall effect of insulin on glucose utilization and glucose production. In this study we show that, by adding a tracer to the oral dose, e.g., of a meal, and by using the labeled version of OMM, OMM* to interpret the data, one can measure the selective effect of insulin on glucose disposal, S* I . Eighty-eight individuals underwent both a triple-tracer meal with the tracer-to-tracee clamp technique, providing a model-independent reference of the R a of ingested glucose (R a meal ref ) and an insulin-modified labeled intravenous glucose tolerance test (IVGTT*). We show that OMM* provides not only a reliable means of tracing the R a of ingested glucose (Ra meal) but also accurately measures S * I . We do so by comparing OMM* Ra meal with the model-independent R a meal insulin action; glucose utilization; tracer-to-tracee activity clamp; intravenous glucose tolerance test; oral glucose tolerance test THE ORAL MINIMAL MODEL METHOD can simultaneously measure insulin secretion, insulin action, and the rate of glucose appearance after meal or glucose ingestion (3, 6, 11, 12) . In particular, the oral glucose minimal model (OMM) measures insulin sensitivity (S I ), as well as the rate of appearance of ingested glucose (R a meal ) (11, 12) . One limitation of the S I index measured by OMM is that S I is a composite index, i.e., it measures the overall effect of insulin to stimulate glucose uptake and inhibit glucose production. At least in theory, the individual contribution of insulin's ability to stimulate glucose uptake can be measured if a glucose tracer is added to the meal. If so, labeled glucose oral data, analyzed by means of an oral labeled minimal model, can provide an estimate of S I (S * I ) reflecting glucose disposal only. This would be reminiscent of the approach that previously led our group to propose the labeled intravenous glucose tolerance test (IVGTT) and its interpretation with the labeled minimal model (10, 14) .
The aim of this study is to develop and validate an oral labeled minimal model (OMM*). We show that OMM* provides reliable estimates of disposal S* I and R a meal . To validate OMM*, we took advantage of a unique data set (11) containing 88 individuals who underwent a triple-tracer labeled meal, as well as a labeled IVGTT (IVGTT*). The triple-tracer labeled meal, thanks to the use of the tracer-to-tracee clamp technique, provided a model-independent reference for the appearance rate of ingested glucose (R a meal ref ) (4 
METHODS

Data
The database consisted of 88 normal subjects [46 males and 42 females: age ϭ 58 Ϯ 2 yr (range 19 -87); body wt ϭ 77 Ϯ 2 kg (range 53-129); BMI ϭ 26.71 Ϯ 0.1 kg/m 2 (range 20 -35); fasting glucose ϭ 92.07 Ϯ 0.7 mg/dl (range 77.29 -105.12)] who received both a triple-tracer mixed meal and an IVGTT*.
Labeled mixed meal. The triple-tracer mixed meal (10 kcal/kg: 45% carbohydrate, 15% protein, 40% fat) contained 1 Ϯ 0.02 g/kg glucose. The meal was labeled with [1- 13 C]glucose (G*), thus allowing us to derive the exogenous, i.e, coming from the meal, glucose (Gmeal) as
where zmeal is the tracer-to-tracee ratio in the meal. Plasma samples were collected at Ϫ120, Ϫ30, Ϫ20, Ϫ10, 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, 260, 280, 300, 360, and 420 min. Figure 1 , A-C, left, shows mean glucose, exogenous glucose, and insulin plasma concentration curves. Beginning at time 0, [6- 3 H]glucose was infused intravenously at a variable rate, mimicking Ra meal. [6,6- 2 H2]glucose was also infused as part of a separate protocol. Because the ratio in plasma between [6- 3 H]glucose and [1-13 C]glucose was maintained almost constant ( Fig. 2A) Figure 1 , A-C, right, shows mean glucose, exogenous glucose, and insulin plasma concentration.
Models
Oral minimal models. For the sake of clarity, a brief description of the "cold" (i.e., unlabeled) oral minimal models (11, 12) precedes the presentation of the new "hot" (i.e., labeled) OMM*. This is done not only because the two oral minimal models hinge on the same monocompartmental structure of glucose kinetics, but also because they share the exogenous glucose input, i.e, R a meal. Denoting by G the total plasma glucose concentration, the rate of glucose disappearance (Rd) and the net hepatic glucose balance (NHGB) (Fig. 3, left) 
where V is the distribution volume. By assuming for R d and NHGB the functional description proposed in Ref. 5 , one obtains OMM:
where SG is fractional (i.e., per unit distribution volume) glucose effectiveness measuring glucose ability per se to promote glucose disposal and inhibit NHGB, I is plasma insulin concentration, X is insulin action on glucose disposal and production, with p 2 and p3 rate constants describing its dynamics and magnitude; b denotes basal values. R a meal is described as a piecewise-linear function with known break point ti and unknown amplitude ␣i: SI is given by
Labeled oral minimal model. OMM is unable to distinguish the individual contribution of glucose production and disposal. To overcome this limitation, a glucose tracer is administered orally and unlabeled glucose and plasma concentrations of the glucose tracer are measured. OMM* relies on G meal (eq. 1), and model equation is
where R d meal is the Rd of Gmeal. By assuming for Rd meal the same functional description proposed previously (10) and for Ra meal the parametric description of Eq. 5, one obtains OMM* (Fig. 3, middle) .
where S* G is fractional (per unit distribution volume) glucose effectiveness measuring glucose ability per se to promote glucose disposal and X* insulin action on glucose disposal with p* 2 and p* 3 rate constants describing its dynamics and magnitude, respectively. OMM* estimates Ra meal together with SI on glucose disposal, with S * I defined as:
Because OMM* and OMM share Ra meal, the two models were identified simultaneously (see Identification).
Reference-labeled model. The validation of OMM* estimates of R a meal and S * I was accomplished by using the following rationale. As mentioned in Data, during the labeled meal, two additional tracers were infused intravenously. In particular, [6- 3 H]glucose was infused to clamp the ratio between concentrations in plasma of [6- 3 H]glucose and ingested glucose tracer. This allowed us to derive reliable and virtually model-independent estimates of R a meal (4) . This estimate, denoted R a meal ref , was used not only as a reference with which OMM* estimate of R a meal was compared but also as a known input of a model with the same structure of OMM* (Fig. 3, right) :
which becomes
By identifying this model, denoted as reference-labeled model (RM*), from Gmeal and insulin data we were able to obtain reference values for OMM* parameters (indicated by IVGTT* minimal models. IVGTT* data were interpreted with the classic single-compartment IVMM (5) and with the labeled twocompartment minimal models (IVMM*) (14) , thus obtaining an estimate of S I and S * I in the same subjects. This, in addition to providing a one-to-one comparison of IVGTT* S* I vs. OMM* S* I , allows us to examine the relationship between SI and S * I in IVGTT and meal.
Identification
Identifiability. Because OMM* (like OMM) is a priori nonidentifiable, the a priori knowledge necessary for its identification was obtained from RM*. OMM* was thus identified by fixing V* and S* G to the mean values obtained with RM*, i.e., V* ϭ V Mean values can safely be used because they are normally distributed (see RE-SULTS). At variance with OMM, where a Bayesian prior on p2 was needed to improve numerical identifiability, OMM* takes advantage of the fact that it shares R a meal with OMM. The simultaneous identification of OMM* and OMM from two measurements (Gmeal and G) relaxes the necessity of using Bayesian priors for p2 and p * 2 . A constraint (11, 12) was imposed to guarantee that the area under the estimated R a meal equals the total amount of ingested glucose, D, multiplied by the fraction that is actually absorbed, f. Because f-values estimated with RM* were not normally distributed (RESULTS), f was Finally, oral tracer measurements provided information as to when Ra meal began to rise in each subject. If tracer concentration is zero up to time ti and is different from zero at time t iϩ1 , then one can safely assume that Ra meal is zero up to ti.
Parameter estimation. All models were numerically identified by nonlinear least squares (7, 9) , as implemented in SAAM II [Simulation Analysis and Modeling software (2)]. Measurement error was assumed to be independent, gaussian, with zero mean and known constant standard deviation. Insulin concentration is the model-forcing function and is assumed to be known without error.
Statistical Analysis.
Data are presented as means Ϯ SE. Two-sample comparisons were done by Wilcoxon signed rank test, and a Shapiro-Wilk test was used to verify whether parameters were normally distributed (significance level set to 5%). Pearson's correlation was used to evaluate univariate correlation.
RESULTS
Parameter estimates of RM*, OMM*, and OMM (simultaneously identified), IVMM*, and IVMM are shown in (Fig. 4) . S * I provided by OMM* and S I * ref were well correlated (r ϭ 0.80, P Ͻ 0.0001; Fig. 5A ), and their mean values were not significantly different (9.64 vs. 9.24 ϫ 10 Ϫ4 dl⅐kg Ϫ1 ⅐min Ϫ1 per U/ml). To quantify how sensitive the OMM/OMM* estimate of S I and S * I to the assumptions made on V, V*, S G , S * G , and f were, we used multiple regression analysis between the percentage deviation of S I (S * I ) and the percentage deviation of V, S G , and f (V*, S * G , f). We found that the percentage deviations of f and S G explain the deviation in S I estimate (0.685, P Ͻ 0.0001), although the deviation of V doesn't contribute significantly to the regression. Conversely, the percentage deviations of f, S* G , and V* explain the deviation in S* I estimate (0.747, P Ͻ 0.0001).
OMM* vs. IVMM*. Correlation between IVMM* and OMM* S* I was significant (r ϭ 0.67, P Ͻ 0.0001; Fig. 5B ) but their values were significantly different (9.64 vs. 11.59 10 Ϫ4 dl⅐kg Ϫ1 ⅐min Ϫ1 per U/ml). S I vs S * I . The relationship between S I and S * I is different during meal and IVGTT. With the oral minimal models, one had 12.24 vs. 9.64 ϫ 10 Ϫ4 dl⅐kg Ϫ1 ⅐min Ϫ1 per U/ml, with S I Ͼ S * I in 81% of the subjects, although for the IVGTT S I was lower than S* I on average (S I ϭ 6.91 vs. S * I ϭ 11.59 ϫ 10 Ϫ4 dl⅐kg Ϫ1 ⅐min Ϫ1 per U/ml) and was so in ϳ90% of the subjects.
DISCUSSION
The OMM method was developed to measure S I under physiological conditions, e.g., a meal or OGTT (12) . In addi- Values are means Ϯ SE, with their precision in parantheses (% coefficient of variation). RM*, reference tracer model; OMM*, labeled version of oral glucose minimal model; OMM, oral glucose minimal model; IVMM*, labeled two-compartment intravenous minimal model; IVMM, intravenous minimal model. †Parameters fixed to reference values. ajpendo.physiology.org tion, OMM can simultaneously estimate the R a in plasma of the ingested glucose, R a meal . The validity of OMM S I and R a meal was recently established (11) . However, OMM S I , although it is an extremely useful index, is a composite measure of insulin action on both glucose production and disposal. Our goal here was to develop a method that specifically measured the ability of insulin to stimulate glucose disposal in physiological conditions. To do this, a tracer was added to the meal, and a labeled OMM (OMM*) was developed. The validity of OMM* S* I and R a meal was assessed by comparing these values to reference values S I * ref and R a meal ref , obtained in the same 88 subjects by means of multiple tracer infusions (4). In addition, S* I calculated with OMM* was compared with that obtained from a labeled insulin-modified IVGTT (IVGTT*) performed in the same 88 individuals.
The R a meal profile obtained with OMM* was very similar to R a meal ref (Fig. 4) . This is an important result, because due to the experimental conditions (i.e., a tracer-to-tracee clamp), R a meal Ϫ4 dl⅐kg Ϫ1 ⅐min Ϫ1 per U/ml, with a satisfactory correlation between the two (r ϭ 0.80, P Ͻ 0.0001; Fig. 5A ).
However, from Fig. 5 , differences exist at the individual level, thus indicating that OMM* is more robust in population rather than individual studies.
The addition of a tracer to the meal, besides allowing segregation of exogenous component, G meal , of plasma glucose concentration G, and thus estimation of insulin sensitivity on glucose disposal, also has beneficial effects on the numerical identifiability of OMM* (and OMM). In fact, OMM*, which is based on G meal data, shares R a meal with OMM, which is based on G data. Thus, for its identification, the unlabeled plasma glucose concentration data G can also be exploited by simultaneously identifying OMM. By doing so, the number of available data doubles, although the number of parameters increases by only two (i.e., from 10 parameters with OMM* alone to 12 with both OMM* and OMM). The improvement in numerical identifiability allowed estimation of p* 2 and p 2 in each individual without having to resort to Bayesian priors as in Refs. 11 and 12. However, parameters V, V*, S G , S * G , and f still need to be fixed to population values derived from the reference model. To quantify how sensitive the OMM/OMM* estimate of S I and S * I to the assumptions made on these parameters were, we investigated, by multiple regression analysis, the relationship between their percentage deviation and that of S I and S * I . We found that the percentage deviations of f and S G explain the deviation in S I estimate (0.685, P Ͻ 0.0001), whereas the deviation of V doesn't contribute significantly to the regression. The percentage deviations of f, S* G , and V* from the fixed values explain the deviation in S* I estimate (0.747, P Ͻ 0.0001).
It is of interest to compare S* I with OMM* and IVGTT*. The two estimates showed a significant correlation, r ϭ 0.67, P Ͻ 0.0001 (Fig. 5B) , although the latter measure was significantly higher: 11.59 vs. 9.64 ϫ 10 Ϫ4 dl⅐kg Ϫ1 ⅐min Ϫ1 per U/ml. The relationship between the cold and hot estimates of S I in IVGTT vs. meal is worth commenting on. The IVGTT results observed in the present 88 subjects are consistent with those previously reported in smaller-size studies (8, 10, 14) . S I was lower than S* I in ϳ90% of the subjects: S I ϭ 6.91 ϫ 10 Ϫ4 vs. S* I ϭ 11.59 ϫ 10 Ϫ4 dl ⅐kg Ϫ1 ⅐min Ϫ1 per U/ml. This relationship is clearly unphysiological, because S I measures the overall effect of insulin on both glucose disposal and production, whereas S* I measures only the effect of insulin on disposal; by definition, S I should be equal to or greater than S * I . Possible reasons for this unexpected pattern have been discussed in Ref. 8 . The relationship between S I and S * I improves dramatically with the OMM, S I ϭ 12.24 ϫ 10 Ϫ4 vs. S * I ϭ 9.64 ϫ 10 Ϫ4 dl⅐kg Ϫ1 ⅐min Ϫ1 per U/ml, with S I Ͼ S * I in 81% of the subjects. However, S I was still less than S * I in 19% of the subjects. It is likely that the improved performance of the oral minimal models stems from the fact that the minimal model assumptions are more tenable during the gentle meal than during the massive IVGTT perturbation, particularly those concerning the description of how NHGB is controlled by glucose and insulin, which are embodied in both cold models. However, the finding that S* I was greater than S I in 19% of the subjects also calls for a revision of this functional description for a meal perturbation.
A comment on the relationship between p 2 and p * 2 in IVGTT and meal, as well as on the difference between intravenous and oral values, is also in order. During both IVGTT and meal, p 2 is approximately one-third of p* 2 (Table 1) . This means that insulin action on the liver has a slower dynamic than insulin action on glucose utilization, and, in all likelihood, the underlying assumption of the classic minimal model, that insulin action on glucose production has the same dynamics of insulin action on glucose utilization, is probably not entirely correct. Moreover, the difference found in p 2 and p * 2 values during IVGTT and meal can be explained by considering the differences between the two tests. During IVGTT, glucose and insulin explore a wider range of values than during the meal (G: 90 -300 vs. 90 -170 mg/dl; I: 4 -120 vs. 4 -60 U/ml), thus possibly uncovering some parameter nonlinearities (1, 13) .
In conclusion, OMM* provides a means of assessing both R a meal and S * I after the ingestion of a carbohydrate-containing meal. Because OMM is simultaneously identified, this approach also permits assessment of the overall effect of insulin on glucose production and disposal (S I ). Furthermore, when the labeled and unlabeled oral minimal models are combined with the oral C-peptide minimal model (6, 15) , insulin secretion and ␤-cell function indexes can also be measured at the same time. However, although in the present study good performance of the method was observed in a wide range of glucose tolerance (S I : 1.52 Ϭ 30.40 ϫ 10 Ϫ4 dl⅐kg Ϫ1 ⅐ min Ϫ1 per U/ml), further studies in diabetic individuals with abnormalities in insulin secretion and action of various degrees of severity are needed to better define the domain of validity of the model. Finally, because insulin action appears to be dependent on the pattern of insulin (1, 13) , future studies will be required to determine whether the ability of insulin to stimulate glucose uptake and suppress glucose production in the presence of the continuously changing insulin concentrations observed after a meal is the same as that observed in the presence of different insulin profiles (e.g., during a hyperinsulinemic clamp).
